



Do you have a clear experimental plan on how to validate your disease-relevant hypothesis, but need funding to translate your idea into a new medicine?

At Novo Nordisk, we have 100 years of experience in discovering, creating and sponsoring innovation to solve healthcare challenges for patients with diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease, and rare blood and endocrine disorders.

Science2Medicine validatioNN is a programme created to support innovators like you. We can provide funding for critical, decision-enabling experiments and feedback and advice from our drug discovery experts – more information about the programme on the following pages.

If you're ready to take your idea to the next level, apply now.

Do you know an exciting novel drug target or mechanism of action that could define next generation medicines for cardiometabolic diseases?

Team up with us and accelerate your drug discovery journey.

# **Science2Medicine validatioNN offers:**

- Funding: quick review process (<1 month); allotment of up to 50,000 Euros for 6–9 months of work to validate your translational idea
- Expert advice: feedback from Novo Nordisk drug discovery/ development experts without ownership claim: you keep IP rights and freedom to publish your research
- Resources: access to Novo Nordisk open innovation compounds/reagents
- Gateway to future collaboration: a foundational partnership with potential for future/long-term collaboration

### **Evaluation criteria:**

- Scientific novelty and impact: new targets, mechanisms of action, pathway analyses, enabling technologies, etc
- Clear hypothesis and experimental plan: a concise description of the idea and research plan
- "Killer experiments": proof of principle experiments that will confirm or refute your hypothesis as valid for continued experimentation

## **Need extra funding?**

Check the validatioNN website for our joint validatioNN proposal calls on specific scientific topics and matched funding opportunities – in collaboration with partner organisations.





If you are seeking inspiration, the following research topics are of particular interest to us, although we welcome any idea within the remit of our disease areas:

#### **DIABETES**

- Efficacy beyond blood glucose lowering, eg co-morbidity risk reduction
- Reversal of insulin resistance
- Prevention of disease progression, eg preservation of beta-cell health (type 1 and type 2 diabetes)

#### **OBESITY**

- Enhancement of energy expenditure
- Modulation of eating behaviour (eg hedonic and reward signalling)
- Modulation of the counter-regulatory mechanisms (eg metabolic set-point)

#### **CARDIOVASCULAR DISEASE**

- Atherosclerotic CVD, HFpEF and cardiomyopathies
- MoAs providing risk reduction additive to LDL/TG lowering and anti-inflammation
- Precision-medicine approaches to heart failure
- Disease-modification (eg gene therapy)

#### **KIDNEY DISEASE**

- CKD/DKD, polycystic kidney disease and glomerulonephritis
- Fibrosis resolution/inhibition of fibrogenesis
- Preservation of vascular and glomerular integrity

## LIVER DISEASE (NASH)

- Fibrosis resolution/inhibition of fibrogenesis
- Suppression of chronic inflammation
- Liver regenerative approaches
- Non-invasive diagnostic biomarkers

#### RARE DISEASES

- Rare, non-malignant haematologic diseases
- Rare endocrine diseases